Illustrative image – not actual.Human Biologicals Institute (HBI), a division of Indian Immunologicals Ltd (IIL), is setting up a human vaccine manufacturing facility at Gachibowli near Hyderabad. An initial investment of around Rs 50 crore is envisaged.
The facility, which would have a capacity of over 100 million doses per annum, would produce vaccines such as DPT, hepatitis-B recombinant, measles, and hepatitis-A vaccines. Civil works are now in progress and commercial production is scheduled to commence from mid-2003 onwards.
The Institute is presently engaged in production of only one vaccine – Abhayrab – an anti-rabies vaccine at its Ooty facility.
IIL, currently imports vaccines for measles, mumps and rubella (MMR) from the Croatia-based Institute of Immunology.
